Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

250 ML sipuleucel-T 200000 CELLS/ML Injection

Known as: SIPULEUCEL-T/LR SUSP INJ 250ML, SIPULEUCEL-T/LACTATED RINGERS INJ,SUSP,250ML [VA Product], sipuleucel-T 50,000,000 CELLS per 250 ML Injection 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
BACKGROUND Sipuleucel-T is an autologous cellular immunotherapy approved by the US Food and Drug Administration for the treatment… Expand
Is this relevant?
Review
2012
Review
2012
  • S. Simoens
  • Human vaccines & immunotherapeutics
  • 2012
  • Corpus ID: 23643231
Sipuleucel-T, a new autologous active cellular immunotherapy, is indicated for metastatic castration-resistant prostate cancer… Expand
Is this relevant?
Review
2012
Review
2012
ZusammenfassungInnerhalb der letzten zwei Jahre hat die Therapie des kastrationsrefraktären Prostatakarzinoms (CRPC) große… Expand
Is this relevant?
2011
2011
The recent approval by the Food and Drug Administration of Makena, a new version of progesterone 17 alpha-hydroxyprogesterone… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
There is no single universally accepted hallmark of antigen presenting cell (APC) activation. Instead a variety of methods are… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?